Female sex, high soluble CD163, and low HDL-cholesterol were associated with high galectin-3 binding protein in type 1 diabetes

Melin, Eva Olga; Dereke, Jonatan; Hillman, Magnus

doi:10.1186/s13293-019-0268-0

Cited by 15 publications

(44 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding was in line with data from previous in vivo and in vitro studies that showed increased expression of Gal-3BP in different phenotypes of metabolic syndrome, including nonalcoholic fatty liver disease, obesity and silent atherosclerosis [16,17]. However, in contrast to some previous studies, our data failed to show a significant correlation between Gal-3BP and clinical lipid profiles or age in women after menopause [9,18]. This may be due to differences in study subjects owing to the selective inclusive criteria and may imply that Gal-3BP is more associated with adipose dysfunction than with fat deposition [19].…”

Section: Discussionsupporting

confidence: 89%

“…Recently, several clinical investigations have suggested that Gal-3BP is related to metabolic dysfunctions ranging from nonalcoholic fatty liver disease to atherosclerosis [5][6][7]. However, few studies have focused on the relationship between insulin resistance and Gal-3BP, and the results remain controversial [8,9]. For this reason, we conducted this study focused on the associations between Gal-3BP and insulin homeostasis and the relevance of Gal-3BP as a biomarker of insulin resistance in the menopausal population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated serum levels of galectin-3 binding protein is associated with insulin resistance in non-diabeteic women after menopause

Chen

Das

Zhuo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Galectin-3 binding protein (GAL-3BP) is one of the major fucosylated glycoprotein family members, and is implicated in nonalcoholic fatty liver disease, lipid dysfunctions and coronary artery disease recently. Here we analyzed the serum concentrations of GAL-3BP in postmenopausal women, to evaluate the association of circulating GAL-3BP and insulin resistance in female after menopause.Method We evaluated serum levels of Gal-3BP in sixty-two non-diabetic women in menopausal status for at least one year. The clinical features, biochemistry profiles and homeostasis model assessment of insulin resistance (HOMA-IR) were obtained routinely.Results Gal-3BP levels increased in women with higher HOMA-IR values and was positively correlated to HOMA-IR. It was also an independent risk factors for HOMA-IR and showed the most influence on HOMA-IR comparing to FPG, TG, age and BMI. The cut-off value of serum Gal-3BP level was 2234.3150 ng/ml with the area under the ROC curve (AUC) 0.68 (HOMA-IR 1.5), 0.81 (HOMA-IR 2.0) and 0.93 (HOMA-IR 2.5).Conclusions Serum levels of Gal-3BP is associated with impaired insulin sensitivity in non-diabetic menopausal women.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Elevated serum levels of galectin-3 binding protein is associated with insulin resistance in non-diabeteic women after menopause

Chen

Das

Zhuo

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…HDL-cholesterol is a well-known predictor for CV disease, but the role of HDL-cholesterol as a causal factor in CV disease is disputed [27]. HDLcholesterol levels have recently been shown to decrease secondary to inflammatory states [25,26].…”

Section: Discussionmentioning

confidence: 99%

“…Lower HDL-cholesterol levels have been demonstrated secondary to inflammatory states [25,26], and are well-known predictors for CV disease [27].…”

Section: Introductionmentioning

confidence: 99%

Low levels of soluble TWEAK, indicating on-going inflammation, were associated with depression in type 1 diabetes: a cross-sectional study

Melin

Dereke

Hillman

2019

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundLow levels of soluble TNF-like weak inducer of apoptosis (sTWEAK) have previously been linked to cardiovascular disease, which is also the case for depression. High levels of galectin-3 and HbA1c, and low levels of HDL-cholesterol, have previously been linked to depression in these patients. The aim was to explore whether low levels of sTWEAK were associated with depression in type 1 diabetes patients. We adjusted for age, sex, galectin-3, HbA1c, HDL-cholesterol, antidepressants, and cardiovascular complications. MethodsCross-sectional design. Type 1 diabetes patients (n=287, men 56%, age18-59 years) were consecutively recruited from one specialist diabetes out-patient clinic. Depression was defined as Hospital Anxiety and Depression Scale-Depression sub scale ≥8 points. Blood samples, anthropometrics and blood pressure were collected, supplemented with data from electronic medical records. ELISA was used to measure sTWEAK and galectin-3. Low sTWEAK was defined as <7.1 ng/ml (<70th percentile), high galectin-3 as ≥2.562 µg/l (≥85th percentile) and high HbA1c as >70 mmol/mol (>8.6%). Non-parametric tests were used. Multiple logistic regression analyses (Backward: Wald) were performed, and calibrated and validated for goodness of fit with the data variables. Results Median (q1, q3) (ng/ml) sTWEAK were for 30 depressed and 257 non-depressed patients 1.5 (1.2, 2.9) and 2.7 (1.3, 13.0) respectively (p =0.021); median (q1, q3) (µg/l) galectin-3 were 1.348 (0.827, 2.850) and 0.916 (0.533, 1.637) respectively (p = 0.005). Four-teen percent of patients with low sTWEAK were depressed, and 2% of patients with high sTWEAK were depressed (p = 0.003). Low sTWEAK (adjusted odds ratio (AOR) (CI)) 9.5 (2.0-46) ), high galectin-3 (AOR (CI) 6.5 (2.3-18.7)), use of antidepressants (AOR (CI) 10.3 (3.3-30.4)), HDL-cholesterol (per mmol/l) (inversely) (AOR (CI) 0.1 (0.03-0.5)), and age (per year) (AOR (CI) 1.05 (1.00-1.09)) were associated with depression. ConclusionsThe depressed patients with type 1 diabetes had lower levels of sTWEAK than the non-depressed, which might contribute to the increased risk for cardiovascular disease and mortality previously demonstrated in patients with depression. Low levels of sTWEAK and HDL-cholesterol and high levels of galectin-3 were independently associated with depression.

show abstract

“…The study has a cross sectional design, and is one of several studies addressing metabolic and inflammatory disturbances in a cohort of patients with T1D [24][25][26][27][28][29][30]. For inclusion and exclusion criteria, number of included and excluded patients, and missing variables, see Fig.…”

Section: Methodsmentioning

confidence: 99%

Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study

2020

Self Cite

View full text Add to dashboard Cite

Background The receptors for advanced glycation end products (RAGE) are increased in atherosclerotic plaques. Soluble (s)RAGE decreases, whereas the extracellular newly identified receptor for advanced glycation end products (EN-RAGE) increases inflammatory responses mediated by RAGE. The aims were to explore whether sRAGE, EN-RAGE and the EN-RAGE/sRAGE ratio, were associated with the use of lipid-lowering drugs (LLD) and/or antihypertensive drugs (AHD) in patients with type 1 diabetes (T1D). Methods Cross-sectional design. T1D patients were consecutively recruited from one diabetes clinic. Blood samples were collected, supplemented with data from electronic health records. sRAGE and EN-RAGE were analysed by enzyme linked immunosorbent assays. An EN-RAGE/sRAGE ratio was calculated. Adjustments were performed with inflammatory and metabolic variables, s-creatinine, depression, smoking, physical inactivity, medication, and cardiovascular complications. Multiple regression analyses were performed. Results In this study 283 T1D patients (men 56%, 18–59 years) were included. One-hundred and thirty LLD users compared to 153 non-users had lower levels of the EN-RAGE/sRAGE ratio (P = 0.009), and 89 AHD users compared to 194 non-users had lower levels of sRAGE (P = 0.031). The use of LLD (inversely) (B coefficient − 0.158, P = 0.033) and the use of AHD (B coefficient 0.187, P = 0.023) were associated with the EN-RAGE/sRAGE ratio. sRAGE (Lg10) (per unit) (adjusted odds ratio (AOR) = 3.5, 95% CI = 1.4–9.1, P = 0.009), EN-RAGE (Lg10) (per unit) (inversely) (AOR 0.4, 95% CI = 0.2–1.0, P = 0.046), age (P < 0.001), and triglycerides (P < 0.029), were associated with LLD. sRAGE (Lg10) (per unit) (inversely) (AOR = 0.2, 95% CI = 0.1–0.5, P = 0.001), diabetes duration, triglycerides, s-creatinine, and systolic BP (all P values < 0.043), were associated with AHD. Conclusions Higher sRAGE levels and lower EN-RAGE levels were linked to the use of LLD, whereas lower sRAGE levels were linked to the use of AHD. No other variables but the use of LLD and the use of AHD were linked to the EN-RAGE/sRAGE ratio. This may be of major importance as sRAGE is an inhibitor and EN-RAGE is a stimulator of inflammatory processes mediated by RAGE.

show abstract

Female sex, high soluble CD163, and low HDL-cholesterol were associated with high galectin-3 binding protein in type 1 diabetes

Cited by 15 publications

References 42 publications

Elevated serum levels of galectin-3 binding protein is associated with insulin resistance in non-diabeteic women after menopause

Elevated serum levels of galectin-3 binding protein is associated with insulin resistance in non-diabeteic women after menopause

Low levels of soluble TWEAK, indicating on-going inflammation, were associated with depression in type 1 diabetes: a cross-sectional study

Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study

Contact Info

Product

Resources

About